Britain: open for business? Why we shouldn’t fear foreign takeovers à la Pfizer
The proposed takeover of British-based pharmaceuticals firm, Astra Zeneca, by US rival Pfizer is now off the agenda: the board of the former has rejected Pfizer’s “final” bid of £69bn to buy it up. This deal has been much in the press in recent weeks—partly due to the size of the would-have-been combined entity—but principally because it would have meant […]









